Allon Therapeutics selected by the Alzheimer's Disease Cooperative Study
Allon Therapeutics Inc. announced that its Alzheimer's clinical development program has been selected by the Alzheimer's disease Cooperative Study (ADCS) in the United States to be included in its submission to receive Phase II clinical trial funding from the U.S. National Institutes of Health (NIH). Gordon McCauley, President and CEO of Allon, said the ADCS has indicated that a Phase II clinical trial evaluating Allon's lead product AL-108 as a treatment for Alzheimer's disease was one of seven projects selected by the ADCS.
The ADCS has indicated that the selected programs will be submitted as a grant application to the NIH in October and a final funding decision made by the NIH in Q1 2006. It is possible that the whole grant application or components parts of it may not be approved. The ADCS was established in 1991 and has become the largest recipient of U.S. government funding for Alzheimer's research and clinical trials.
Allon announced March 2, 2005 that it had completed dosing for its Phase Ia human clinical trial evaluating AL-108 as a treatment for Alzheimer's disease. Data from the Phase Ia trial will be analyzed by the end of the second quarter. The next clinical development step for AL-108 is a Phase Ib trial to evaluate AL-108 in healthy adults most at risk for Alzheimer's disease, and ultimately in diagnosed Alzheimer's patients, subject to appropriate regulatory approval. Allon has shown in preclinical studies that AL-108 has activity that may reduce plaque and tangle formation, removes plaques and promotes the repair of neurofibrillary tangles. AL-108 may also protect healthy neurons from damage cause by the formation of plaques and tangles.
Other news from the department science
